Tevogen Bio Holdings (TVGN) Non Operating Investment Income (2022 - 2023)

Tevogen Bio Holdings (TVGN) reported Non Operating Investment Income of $317365.0 for Q4 2023, down 88.42% on a YoY basis from $2.7 million in Q4 2022, and down 5.12% quarter-over-quarter from $334475.0 in Q3 2023.

Tevogen Bio Holdings (TVGN) Non Operating Investment Income (2022 - 2023) Analysis & Trends

Tevogen Bio Holdings has reported Non Operating Investment Income for 2 years, with the latest figure at $317365.0 in Q4 2023.

  • For the quarter ending Q4 2023, Non Operating Investment Income fell 88.42% year-over-year to $317365.0; the trailing twelve-month figure through Dec 2023 stood at $2.7 million (down 44.74% YoY), and the FY2023 full-year result was $2.7 million, down 44.74% from the prior year.
  • Non Operating Investment Income for Q4 2023 stood at $317365.0, down from $334475.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $2.7 million in Q4 2022, with the low at $140891.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - 235,807.00
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - 230,000.00
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 Tevogen Bio Holdings 182.04 Mn 181.35 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 317,365.00
Dec 31, 2023 317,365.00
Sep 30, 2023 334,475.00
Sep 30, 2023 334,475.00
Jun 30, 2023 302,524.00
Jun 30, 2023 302,524.00
Mar 31, 2023 1.78 Mn
Mar 31, 2023 1.78 Mn
Dec 31, 2022 2.74 Mn
Dec 31, 2022 2.74 Mn
Sep 30, 2022 1.74 Mn
Sep 30, 2022 1.74 Mn
Jun 30, 2022 327,833.00
Jun 30, 2022 327,833.00
Mar 31, 2022 140,891.00
Mar 31, 2022 140,891.00